ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use

Completed

Conditions: HIV-1 Patients

First Posted Date: 2011-06-23

Last Posted Date: 2011-10-17

Lead Sponsor: Abbott

Target Recruit Count: 2288

Registration Number: NCT01379703

Locations: 🇨🇿
Site Ref # / Investigator 57102, Brno, Czech Republic
🇨🇿
Site Ref # / Investigator 5344, Prague 8, Czech Republic
🇵🇱
Site Ref # / Investigator 56886, Szczecin, Poland

and more 100 locations

Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis

Completed

Conditions: Bronchitis

Interventions: Drug: Clarithromycin modified release 500 mg

First Posted Date: 2011-05-17

Last Posted Date: 2013-02-06

Lead Sponsor: Abbott

Target Recruit Count: 220

Registration Number: NCT01354938

Locations: 🇵🇰
Site Ref # / Investigator 54037, Peshawar, KP, Pakistan
🇵🇰
Site Ref # / Investigator 54026, Faisalabad, Pakistan
🇵🇰
Site Ref # / Investigator 54029, Faisalabad, Pakistan

and more 25 locations

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

Phase 1

Completed

Conditions: Hypogonadal Males

Interventions: Drug: ABT-SLV361
Drug: placebo

First Posted Date: 2011-05-03

Last Posted Date: 2011-11-03

Lead Sponsor: Abbott

Registration Number: NCT01346319

Locations: 🇺🇸
Site Reference ID/Investigator# 51964, Fort Myers, Florida, United States

A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: ABT-869, linifanib
Drug: [14C]linifanib

First Posted Date: 2011-02-01

Last Posted Date: 2012-09-21

Lead Sponsor: Abbott

Target Recruit Count: 3

Registration Number: NCT01286974

Locations: 🇺🇸
Site Reference ID/Investigator# 40942, Cleveland, Ohio, United States
🇺🇸
Site Reference ID/Investigator# 53663, Cleveland, Ohio, United States

Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.

Phase 1

Withdrawn

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: briakinumab

First Posted Date: 2010-12-15

Last Posted Date: 2011-10-21

Lead Sponsor: Abbott

Target Recruit Count: 12

Registration Number: NCT01260844

A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: adalimumab

First Posted Date: 2010-11-01

Last Posted Date: 2011-04-26

Lead Sponsor: Abbott

Target Recruit Count: 100

Registration Number: NCT01231321

Locations: 🇷🇺
Site Ref # / Investigator 17682, Kazan, Russian Federation
🇷🇺
Site Ref # / Investigator 18081, Saint Petersburg, Russian Federation
🇷🇺
Site Ref # / Investigator 17681, Moscow, Russian Federation

and more 2 locations

Evaluation of the Effectiveness, Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients

Completed

Conditions: Osteoarthritis
Pain
Morning Stiffness

First Posted Date: 2010-10-21

Last Posted Date: 2013-09-20

Lead Sponsor: Abbott

Target Recruit Count: 519

Registration Number: NCT01226095

Locations: 🇪🇬
Site Reference ID/Investigator# 42584, Alexandria, Egypt
🇪🇬
Site Reference ID/Investigator# 42585, Alexandria, Egypt
🇪🇬
Site Reference ID/Investigator# 42591, Alexandria, Egypt

and more 12 locations

Effect of Digene Total (Buffered Pantoprazole) on 24 Hour Gastric Potential Hydrogen (pH) in Patients From Acid Peptic Disorder After Single and Repeated Dosing.

Phase 4

Completed

Conditions: Acid Peptic Disorder

Interventions: Drug: Buffered pantoprazole

First Posted Date: 2010-10-05

Last Posted Date: 2012-12-28

Lead Sponsor: Abbott

Target Recruit Count: 47

Registration Number: NCT01214408

Locations: 🇮🇳
Site Reference ID/Investigator# 42043, Chennai, India

Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America

Completed

Conditions: Cardiovascular Diseases

Interventions: Drug: Niacin

First Posted Date: 2010-09-13

Last Posted Date: 2014-06-06

Lead Sponsor: Abbott

Target Recruit Count: 128

Registration Number: NCT01200160

Locations: 🇲🇽
Site Reference ID/Investigator# 42110, Aguascalientes, Mexico
🇲🇽
Site Reference ID/Investigator# 42106, Mexico City DF, Mexico
🇲🇽
Site Reference ID/Investigator# 42104, Tijuana, Baja California Norte, Mexico

and more 19 locations

Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane

Completed

Conditions: Anesthesia, General

First Posted Date: 2010-09-13

Last Posted Date: 2012-01-26

Lead Sponsor: Abbott

Target Recruit Count: 4000

Registration Number: NCT01199471

Locations: 🇨🇳
Site Reference ID/Investigator# 43055, Zhejiang, China
🇨🇳
Site Reference ID/Investigator# 43054, Zhejiang, China
🇨🇳
Site Reference ID/Investigator# 43073, Guangzhou, Guangdong, China

and more 37 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy